Japan Tissue Engineering Co., Ltd. (TYO:7774)
556.00
+2.00 (0.36%)
At close: Feb 6, 2026
Japan Tissue Engineering Revenue
Japan Tissue Engineering had revenue of 511.60M JPY in the quarter ending December 31, 2025, a decrease of -6.20%. This brings the company's revenue in the last twelve months to 2.26B, down -7.23% year-over-year. In the fiscal year ending March 31, 2025, Japan Tissue Engineering had annual revenue of 2.46B, down -2.35%.
Revenue (ttm)
2.26B
Revenue Growth
-7.23%
P/S Ratio
10.00
Revenue / Employee
11.07M
Employees
204
Market Cap
22.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.46B | -59.00M | -2.35% |
| Mar 31, 2024 | 2.51B | 482.00M | 23.72% |
| Mar 31, 2023 | 2.03B | -71.00M | -3.38% |
| Mar 31, 2022 | 2.10B | -154.00M | -6.82% |
| Mar 31, 2021 | 2.26B | -52.00M | -2.25% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.61B |
| RaQualia Pharma | 3.05B |
| ReproCELL | 2.63B |
| Immuno-Biological Laboratories | 1.01B |
| Stella Pharma | 992.00M |
| AnGes | 818.00M |
| CellSeed | 161.00M |
| Renascience | 87.00M |